27 Million € Lead Investment for Antisense Pharma
Antisense Pharma is a pioneer in the development of Antisense medicines. The substances developed with the aid of modern platform technology silence genes and thereby prevent the production of proteins that can cause illness. This means the cancer is no longer fought symptomatically, but at its source. The product pipeline comprises active substances for malignant brain tumours, bowel cancer, pancreatic cancer, malignant melanoma and other types of tumours in different stages of preclinical and clinical development. Antisense Pharma was awarded the Bavarian Innovation Prize and the German Foundation Prize. In addition to the MIG Fund, which is already has a stake in Antisense Pharma via the MIG Fund 1 and 2, private investors are also taking part such as S-Refit, the tbg Technologie-Beteiligungs-Gesellschaft mbH and the Technologie Beteiligungsfonds GmbH & Co. KG. The MIG-Verwaltungs AG is an initiator of several sealed venture capital funds, which invest in innovative, medium-sized high technology companies not listed on the stock market. Correspondingly they acquire direct holdings in these companies. The new fund MIG 5 has a placement volume of 70 million €. With the signatures of the shareholders, one of the largest German biotechnology deals of the last year was sealed today.
For more information see: